Verily Secures $300 Mn to Scale its AI-based Healthcare Strategy

The funding round was led by Series X Capital and includes participation from new and existing investors such as UCHealth and the University of Colorado Anschutz, with Alphabet retaining a minority stake in the company.

Verily, a global healthtech company, has raised $ 300 million in fresh funding to accelerate its AI roadmap and expand its precision health capabilities.

The funding round was led by Series X Capital, with participation from both new and existing investors, including UCHealth and the University of Colorado Anschutz while Alphabet retains a minority stake in the company.

Verily has changed its legal structure from an LLC to a corporation, adopting the new name Verily Health.

The newly infused capital will be deployed to advance Verily’s AI platforms, namely Verily Pre and Verily Me capabilities, with a focus on improving clinical research, care delivery, and population health management.

Additionally, the company seeks to build scalable AI solutions and data infrastructure to support precision medicine and personalized care

The company further plans to accelerate its AI-native precision health platform strategy and roadmap, which is expected to enable customers to harmonize their healthcare data, model, and deploy actionable intelligence into research and care workflows.

Furthermore, Verily is also collaborating with global healthtech platforms such as Nvidia to strengthen its healthcare solutions by integrating NVIDIA’s AI technology stack into its Pre platform to speed up research and analysis and accelerate the development of AI agents and models for clinical care and research.

Recently, the company had also announced new partnerships, including a new collaboration with Samsung’s Galaxy Watch to help life sciences customers accelerate clinical research through biomarker development on the Pre platform, and a strategic partnership with Salesforce, announcing integration of the Verily Pre Platform with Agentforce Health to power enterprise precision health solutions.

Commenting on the new capital infusion, Stephen Gillett, Chairman and CEO of Verily, said, “Today is an important step in our mission to bring the promise of precision health to everyone. From research to care, our customers need solutions that bring the best of clinical and scientific rigor together with AI to deliver the next generation of healthcare - one that is as precise as it is personal. Series X Capital, Alphabet, UCHealth, the University of Colorado Anschutz, and our many investors will be fantastic partners in this transformation of healthcare.”

Stay tuned for more such updates on Digital Health News